Back to UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

DAWNDAWN
11 quarters

Position history for UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's holdings in DAY ONE BIOPHARMACEUTICALS I

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC previously held 0 shares of DAWN (DAY ONE BIOPHARMACEUTICALS I), worth $0 as of 2026-Q2.

Final Value

$0

Final Shares

0

Total Value Change

-$208,780

Total Shares Change

-14,300

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Exited
0
-100.0%
$00.0%$21.45
0
2026-Q1
Increased
136,991
+10.1%
$2.9M0.0%$10.03
29
2025-Q4
Increased
124,422
+7.0%
$1.2M0.0%$9.18
27
2025-Q3
Decreased
116,245
-33.7%
$819,5280.0%$6.99
0
2025-Q2
Increased
175,416
+56.2%
$1.1M0.0%$6.47
36
2025-Q1
Increased
112,279
+48.6%
$890,3720.0%$8.07
34
2024-Q4
Increased
75,579
+15.9%
$957,5860.0%$12.58
29
2024-Q3
Decreased
65,193
-6.5%
$908,1380.0%$14.16
0
2024-Q2
Increased
69,730
+84.1%
$960,8780.0%$13.78
39
2024-Q1
Increased
37,879
+164.9%
$625,7610.0%$16.52
39
2023-Q4
New
14,300
-
$208,7800.0%$14.60
32

Other major holders of DAWN: FMR LLC, RA CAPITAL MANAGEMENT, L.P., BlackRock, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used